ING Knock-Out RO/ DE000NG8RW00 /
13/11/2024 16:36:11 | Chg.-0.060 | Bid17:14:36 | Ask17:14:36 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
12.140EUR | -0.49% | - Bid Size: - |
- Ask Size: - |
ROCHE I | 170.4238 CHF | 31/12/2078 | Call |
Newsfile Corp
11/10
JRR Marketing Announces Launch of New Book "5 Ways to Get Strangers to Want to Buy Your Stuff" to He...
Newsfile Corp
02/10
First Phosphate Corp. communique la publication d'une note de recherche universitaire relative aux g...
GlobeNewswire
26/08
First Patient Dosed with LIXTE’s LB-100 in New Clinical Trial to Treat Colorectal Cancer, Collaborat...
GlobeNewswire
18/06
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
14/06
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire
11/06
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D ...
GlobeNewswire
09/05
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson...
GlobeNewswire
03/04
UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Inju...
GlobeNewswire
02/04
Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting C...
GlobeNewswire
14/03
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides C...
GlobeNewswire
26/02
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Ro...
GlobeNewswire
21/02
REPARE ALERT: Bragar Eagel & Squire, P.C. is Investigating Repare Therapeutics Inc. on Behalf of Rep...